Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab rav...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Hematol Oncol
Asıl Yazarlar: Schönfeld, Kurt, Zuber, Chantal, Pinkas, Jan, Häder, Thomas, Bernöster, Katrin, Uherek, Christoph
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2017
Konular:
Letter to the Editor
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5225632/
https://ncbi.nlm.nih.gov/pubmed/28077160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0380-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller